Nathan Hacker

Nathan Hacker is a Senior Scientist at Eli Lilly and Company, with a strong background in drug discovery and early development. Previously, Nathan served as a Laboratory Scientist II at Labcorp Drug Development, where they applied expertise in Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) to support various drug development projects. With over five years of experience, Nathan specializes in immunoassay development and has expanded into cell-based assays and flow cytometry. They hold a Bachelor of Science in Biology from Indiana University–Purdue University Indianapolis, where they completed their degree in 2018. Nathan is passionate about advancing health and innovation in the field of drug development.